Ikena Oncology is again shrinking its herd and signaling a tough fight ahead as one of two assets, a TEAD1-selective Hippo pathway inhibitor, is cut. The cancer biotech is laying off more than half of ...

Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...

One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...

I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on ...

CAMBRIDGE, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ...

EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on ...